Online inquiry

IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12113MR)

This product GTTS-WQ12113MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FOLR1 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000802.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2348
UniProt ID P15328
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12113MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11941MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ3667MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ14296MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ13086MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ4197MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ2803MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ12948MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ9611MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW